Luis-Esteban Tamariz-Amador, MD, University Clinic of Navarra, Pamplona, Spain, briefly discusses a study exploring the value of using 18FDG-PET/CT when treating patients with relapsed/refractory (R/R) multiple myeloma with CAR-T cells. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
